Introduction

Enanta Pharmaceuticals is a research and development company that uses its novel chemistry approach and drug discovery capabilities to create best in class small molecule drugs in the anti-infective field.

At the heart of Enanta is its commitment to innovative chemistry that surpasses traditional medicinal chemistry approaches. Enanta is developing novel protease and polymerase inhibitors targeted against the Hepatitis C virus (HCV). Additionally, the Company has created a new class of macrolide antibiotics, called Bicyclolides that overcomes bacterial resistance. Antibacterial focus areas include superbugs, respiratory tract infections, and intravenous and oral treatments for hospital and community MRSA.

Enanta Pharmaceuticals is a privately held company with offices in Watertown, MA.

click here for more


Press Releases
April 10, 2008
Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA

November 1, 2007
Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies

December 12, 2006
Abbott and Enanta Form Worldwide Alliance to Develop and Commercialize HCV Protease Inhibitors

January 19, 2006

Enanta Pharmaceuticals Announces Initiation of Phase 2 Studies in North America on First-in-Class Antibiotic EDP-420 for the Treatment of Community Acquired Pneumonia

Archives